Dapiprazole: will it affect the standard of care for pupillary dilation?
One of the most controversial clinical issues in optometry is the use of "routine" pupillary dilation. Many optometrists are still reluctant to employ routine dilation because of concerns regarding patient inconvenience, angle-closure glaucoma, or systemic side effects. Dapiprazole, a new alpha-adrenergic blocking agent, is now available to reverse the effects of tropicamide- or phenylephrine-induced mydriasis. This article discusses the advantages, clinical uses, limitations, and legal aspects of this mydriatic antagonist in optometric practice.
J D
JD
Bartlett
J G
JG
Classé
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D005128:Eye Diseases / Q000175:diagnosis; D006801:Humans; D009184:Mydriatics / Q000037:antagonists & inhibitors; D010656:Phenylephrine / Q000627:therapeutic use; D010879:Piperazines; D011680:Pupil / Q000187:drug effects*; D014230:Triazoles / Q000627:therapeutic use*; D014331:Tropicamide / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D009184:Mydriatics; D010879:Piperazines; D014230:Triazoles; D010656:Phenylephrine; C035289:dapiprazole; D014331:Tropicamide